AC Immune's ACI-7104 Parkinson's Drug Shows Positive Phase 2 Interim Data; Cash Runway Extended to 2027
ACIU has more than doubled off its 52-week low of $1.43.
Summary
AC Immune SA announced positive interim Phase 2 results for its wholly-owned active immunotherapy ACI-7104 for early Parkinson's disease, suggesting the treatment may slow disease progression. The company also initiated a Phase 1 trial for its NLRP3 inhibitor ACI-19764 and, following a strategic review, reduced its workforce by approximately 30% to extend its cash runway to the end of Q3 2027. These updates are highly material for a clinical-stage biopharmaceutical company. The positive Phase 2 data for ACI-7104 represents a significant de-risking event for a key pipeline asset, potentially indicating a disease-modifying treatment for Parkinson's. The extended cash runway provides crucial financial stability, alleviating near-term funding concerns and supporting continued pipeline development. Investors will now watch for further value-inflection points, including interim results for ACI-24 in H1 2026 and full 24-month data for ACI-7104 in Q3 2026.
At the time of this announcement, ACIU was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $296.8M. The 52-week trading range was $1.43 to $4.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.